Ironwood Pharmaceuticals Inc. (IRWD)

16.71
0.44 2.57
NASDAQ : Health Technology
Prev Close 17.15
Open 17.03
Day Low/High 16.55 / 17.52
52 Wk Low/High 12.89 / 21.20
Volume 1.21M
Avg Volume 881.80K
Exchange NASDAQ
Shares Outstanding 139.18M
Market Cap 2.67B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 34 th Annual J.

Insider Trading Alert - ANCX, IRWD And MPLX Traded By Insiders

Insider Trading Alert - ANCX, IRWD And MPLX Traded By Insiders

Stocks with insider trader activity include ANCX, IRWD and MPLX

Astellas And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Conducted In Japan

Astellas And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Conducted In Japan

Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc.

Ironwood Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation

Ironwood Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase II clinical trial of linaclotide conducted in adults with opioid-induced constipation (OIC) met its primary endpoint.

First Week of January 2016 Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week of January 2016 Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the January 2016 expiration.

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its third quarter 2015 and recent business activities.

Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701

Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the initiation of a Phase Ib clinical study of IW-1973 and a Phase Ia clinical study of IW-1701, both of which are investigational soluble guanylate cyclase...

Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation

Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today the initiation of a Phase IIb clinical trial evaluating two orally-administered colonic release formulations of...

'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon

'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon

Cramer says keep Sierra Wireless, avoid Rackspace Hosting and take Weight Watchers gain and go.

Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities

Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities

One company's awful earnings can drag others down in the sector, making bargains for the taking, Cramer syas.

First Week of December 18th Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week of December 18th Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the December 18th expiration.

Ironwood Highlights Refractory GERD And Constipation Research At The American College Of Gastroenterology 2015 Annual Scientific Meeting

Ironwood Highlights Refractory GERD And Constipation Research At The American College Of Gastroenterology 2015 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced a series of oral and poster presentations at the American College of Gastroenterology 2015 Scientific Meeting in Honolulu, HI, October 16 to 21, 2015.

Ironwood Pharmaceuticals To Host Third Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals To Host Third Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2015 investor update conference call and webcast at 4:30 p.

Ironwood Reports Positive Top-Line Results From Phase III Trial Of 72 Mcg Linaclotide In Adults With Chronic Idiopathic Constipation

Ironwood Reports Positive Top-Line Results From Phase III Trial Of 72 Mcg Linaclotide In Adults With Chronic Idiopathic Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase III clinical trial of its 72 mcg dose of linaclotide in adults with chronic idiopathic constipation (CIC) met the primary endpoint.

Ironwood Pharmaceuticals (IRWD) Flagged As Strong On High Volume

Ironwood Pharmaceuticals (IRWD) Flagged As Strong On High Volume

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015 at 12:55 p.

First Week of IRWD October 16th Options Trading

First Week of IRWD October 16th Options Trading

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the October 16th expiration.

Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its second quarter 2015 and recent business activities.

Ironwood And Allergan Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S.

Ironwood And Allergan Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement with Allergan plc for the U.

Ironwood Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973

Ironwood Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today positive top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase (sGC) stimulator.

Ironwood Pharmaceuticals To Host Second Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2015 investor update conference call and webcast at 4:30 p.

First Week of IRWD February 2016 Options Trading

First Week of IRWD February 2016 Options Trading

Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the February 2016 expiration.

Synergy Rises on Positive Results from Constipation Drug Study

Synergy Rises on Positive Results from Constipation Drug Study

Synergy Pharmaceuticals' experimental drug plecanatide significantly reduced chronic constipation compared to a placebo, achieving the primary goal of a late-stage study.

Synergy A Potential Takeover Target After Constipation Drug Data

Synergy A Potential Takeover Target After Constipation Drug Data

The shares of Synergy Pharmaceuticals are rallying after the company announced that its chronic constipation treatment had met its primary endpoint in a Phase 3 clinical trial.

Ironwood Pharmaceuticals (IRWD): Heavy Pre-Market Activity

Ironwood Pharmaceuticals (IRWD): Heavy Pre-Market Activity

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a pre-market mover with heavy volume candidate

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a pre-market mover with heavy volume candidate

Ironwood Pharmaceuticals Prices $300 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals Prices $300 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the pricing of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2022 (the Notes).

Ironwood Pharmaceuticals Announces Proposed Offering Of $300 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals Announces Proposed Offering Of $300 Million Of Convertible Senior Notes

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior unsecured notes that will mature...

TheStreet Quant Rating: D (Sell)